

FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A




FIG. 3B

[illegible]

FIG. 4B





FIG. 4A






FIG. 4D




FIG. 4C

FIG. 4E




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6A

FIG. 6B

FIG. 6C




FIG. 6D




FIG. 6E




FIG. 7A




FIG. 7B





FIG. 7C



No. eggs laid in 90 min
12.5 mM 5-HT





Fluoxetine (High concentrations) / Non-MOD-5 CeSERT targets
paralysis
egg laying
nose contraction

FIG. 8C




FIG. 8B

MOD-5 CeSERT
MOD-1 5-HT-Gated Chloride Channel
GOA-1 G-protein

FIG. 8A

RECEIVED
OCT 1 8 2002
FBI/DOJ